期刊
JOURNAL OF MEDICAL TOXICOLOGY
卷 17, 期 4, 页码 411-424出版社
SPRINGER
DOI: 10.1007/s13181-021-00833-8
关键词
Immunotherapy; Checkpoint inhibitor; Chemotherapy; Toxicity; Adverse events
类别
Cancer immunotherapy, particularly immune checkpoint inhibitors, has drastically changed cancer treatment by activating the immune system to target tumor cells. However, these therapies can lead to immune-related adverse effects affecting various organ systems, which may range from mild to life-threatening. Management requires multidisciplinary coordination for individualized care and prompt recognition of toxic effects.
Cancer immunotherapy, which leverages features of the immune system to target neoplastic cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly expanded in the past two decades. Immune checkpoint inhibitors represent one drug class within immunotherapy with its first agent FDA-approved in 2011. Immune checkpoint inhibitors act by disrupting inhibitory signals from neoplastic cells to immune effector cells, allowing activated T-cells to target these neoplastic cells. Unique adverse effects associated with immune checkpoint inhibitors are termed immune-related adverse effects (irAEs) and are usually immunostimulatory in nature. Almost all organ systems may be affected by irAEs including the dermatologic, gastrointestinal, pulmonary, endocrine, and cardiovascular systems. These effects range from mild to life-threatening, and their onset can be delayed several weeks or months. For mild irAEs, symptomatic care is usually sufficient. For higher grade irAEs, discontinuation of therapy and initiation of immunosuppressive therapy may be necessary. The management of patients with irAEs involves multidisciplinary care coordination with respect to the long-term goals the individual patient. Clinicians must be aware of the unique and sometimes fatal toxicologic profiles associated with immunotherapies to ensure prompt diagnosis and appropriate management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据